Monte Rosa Therapeutics, Inc. GLUE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.21M-95.0% | $2.78M-95.4% | $12.77M+38.5% | $23.19M+394% | $84.93M+7,882% | ||
| $44.07M+36.9% | $41.98M+8.0% | $36.68M+32.8% | $30.65M+9.3% | $32.19M+19.1% | ||
| $10.18M+16.9% | $10.52M+19.8% | $9.07M+11.5% | $8.1M-12.8% | $8.7M-3.1% | ||
| $54.24M+32.6% | $52.5M+10.2% | $45.74M+28.0% | $38.75M+3.8% | $40.89M+13.6% | ||
| $54.24M+32.6% | $52.5M+10.2% | $45.74M+28.0% | $38.75M+3.8% | $40.89M+13.6% | ||
| -$50.03M-214% | -$49.72M— | -$32.98M-24.3% | -$15.55M+52.3% | $44.04M+226% | ||
| -1,188.5%-1,240pp | -1,787.7%— | -258.3%+29.6pp | -67.1%+628pp | 51.9%+3,336pp | ||
| $5.59M+62.6% | $3.69M+42.2% | $2.75M-5.0% | $3.07M+16.3% | $3.44M+40.8% | ||
| $5.58M+52.1% | $3.64M+40.1% | $2.72M-0.8% | $4.46M+72.5% | $3.67M+19.9% | ||
| $0-100% | $0— | $0— | $0— | $59K— | ||
| -$44.45M-193% | -$46.08M— | -$30.26M-27.2% | -$11.1M+63.1% | $47.71M+250% | ||
| $52K-93.7% | $0-100% | -$3.18M-4,575% | $1.2M+376% | $822K+890% | ||
| -$44.5M-195% | -$46.11M— | -$27.08M-13.5% | -$12.3M+59.4% | $46.89M+247% | ||
| -1,057.1%-1,112pp | -1,658%— | -212.1%+46.8pp | -53%+593pp | 55.2%+3,060pp | ||
| -$0.45-179% | -$0.55— | -$0.33-13.8% | -$0.15+65.1% | $0.57+208% | ||
| 99.9M+20.4% | 83.1M+12.4% | 82.4M+0.5% | 82.2M+15.4% | 83M+37.9% | ||
| 99.9M+21.6% | 83.1M+12.4% | 82.4M+0.5% | 82.2M+15.4% | 82.1M+36.6% | ||
| $5.59M+62.6% | $3.69M+42.2% | $2.75M-5.0% | $3.07M+16.3% | $3.44M+40.8% | ||
| -$0.45-179% | -$0.55— | -$0.33-13.8% | -$0.15+65.1% | $0.57+208% | ||
| -$0.45-179% | -$0.55— | -$0.33-13.8% | -$0.15+65.1% | $0.57+208% | ||
| -$45.42M-197% | -$46.72M— | -$26.96M-14.6% | -$12.34M+59.3% | $46.91M+247% | ||
| $974K+4,538% | —— | —— | —— | $21K+425% | ||
| -$8K-105% | $0-100% | -$29K+81.0% | $1.39M+2,723% | $173K-72.1% | ||
| $0-100% | $0— | $0— | $0— | $59K— | ||
| -$55K-14.6% | —— | —— | —— | -$48K— | ||
| -$50.03M-214% | -$49.72M— | -$32.98M-24.3% | -$15.55M+52.3% | $44.04M+226% | ||
| -$48.01M-204% | -$47.63M— | -$30.88M-26.4% | -$13.43M+56.1% | $46.08M+239% | ||
| -$48.01M-204% | -$47.63M— | -$30.88M-26.4% | -$13.43M+56.1% | $46.08M+239% | ||
| -1,140.3%-1,195pp | -1,712.6%— | -241.9%+23.2pp | -57.9%+593pp | 54.3%+3,160pp | ||
| -$50.03M-214% | -$49.72M— | -$32.98M-24.3% | -$15.55M+52.3% | $44.04M+226% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Monte Rosa Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.